{"denoms":[{"counts":[{"groupId":"BG000","value":"74"}],"units":"Participants"}],"groups":[{"description":"Oral pomalidomide 4 mg on Days 1-21 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity","id":"BG000","title":"Pomalidomide"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.25","value":"64.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"42"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"American Indian or Alaska Native"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Native Hawaiian or Other Pacific Islanders"},{"categories":[{"measurements":[{"groupId":"BG000","value":"52"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}],"title":"Not Collected"}],"paramType":"NUMBER","title":"Race","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"49"}]}],"title":"Not Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}],"title":"Not Collected"}],"paramType":"NUMBER","title":"Ethnicity","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"74"}]}]}],"paramType":"NUMBER","title":"Participants with Prior Anti-Myeloma (MM) Therapies","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}],"title":"Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"50"}]}],"title":"Stage III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Missing"}],"description":"Stages are:\n\nStage I: Hemoglobulin \\> 10 g/dL; serum calcium normal on roentgenogram; normal bone structure or solitary bone plasmacytoma only; Low M-component production rates (IgG value \\< 5 g/dL, IgA value \\< 3 g/dL; Bence Jones protein \\< 4 g/24h)\n\nStage II: Overall data as minimally abnormal for stage I, and no single value as abnormal as defined for stage III\n\nStage III: 1 or more of below:\n\nHemoglobin \\< 8.5 g/dL; serum calcium \\> 12 mg/dL; Advanced lytic bone lesions (scale 3); High-M-component production rates (IgG value \\> 7 g/dL, IgA value \\> 5 g/dL; Bence Jones protein \\> 12 g/24h)","paramType":"NUMBER","title":"Durie-Salmon Multiple Myeloma Stage before Study Entry","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"3.72","value":"7.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Time From First Pathologic Diagnosis","unitOfMeasure":"years"}],"populationDescription":"The intent-to-treat (ITT) population was defined as all enrolled participants."}